NWK Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

NWK Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-8,538	Closed	-$3.89M	–	68
2025 Q3	$3.89M	Buy	+8,538	New	+$3.48M	1.32%	28

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

NWK Group's ALNY Position: Q4 2025 in Review

NWK Group sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 8,538 shares — an estimated $3.89M sold.

NWK Group first reported a position in ALNY in Q3 2025 and held it in 1 quarter. The position peaked at $3.89M in Q3 2025. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

NWK Group reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
NWK Group sold 8,538 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $3.89M.
NWK Group first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 1 quarter.
NWK Group's Alnylam Pharmaceuticals position peaked at $3.89M in Q3 2025.
851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on NWK Group's 13F filing for Q4 2025, filed 9 Feb 2026.